Please note this website is not updated anymore as the LBI-CR was integrated into its partner universities.
for current research activities of Richard and his team!
The group of Richard Moriggl is focused on the JAK-STAT core cancer pathway. The group studies hematopoietic cancer with a focus on myeloproliverative neoplasm, melanoma, sarcoma, colon and liver cancer. Molecular mechanisms of transcription factors and kinases are analyzed to gain insights into mechanisms of action to control cellular proliferation/survival, PI3K-Akt activation or metabolism in context of cancer establishment and progression. Moreover, the group is involved in new targeted therapy developments and establishes test systems for translational cancer research.
The research team of Richard Moriggl has now been integrated into the Partner University of Veterinary Medicine, Vienna
The research team of Richard Moriggl in 2017
With our research we hope to bridge the gap between laboratory animal models and human patients. We are focussing on transgenic cancer mouse models, to investigate core cancer pathways for their roles in driving the establishment or progression of cancer. We will continue to define key molecules of core cancer pathways as oncogenes or tumour suppressors, often specific to particular cell types or diseases. Moreover, oncogenes or tumour suppressors are dependent on the mutational gene driver context, prominent themes in the RM lab. Our understanding of the context is currently limited and improvements will be essential to enable molecular insights into disease processes. We work closely with genetic/transgenetic clinical research (both human and animal) and with histo-pathology labs, both within Austria and international. Group members focus mainly on aberrant signal transduction and molecular mechanisms of cancer causing disease often involving transgenic animal models and patient sample analysis. We are a research team of approximately 10 people, consisting mainly of PhD and Master students, all focused on translational cancer research. The group of RM formed in 2006 and RM supervises several national and international research projects. Further grant money was attracted through international collaboration.
About Richard Moriggl
Richard Moriggl is professor for "Functional Cancer Genomics" in a joint appointment of the University for Veterinary Medicine, Vienna and the Medical University Vienna.
RM is an internationally reputed expert in JAK/STAT signalling and cancer research. As of March 2016 he has more than 110 PubMed
based publications with over 7.000 citations and an h-index of 43 according to his google scholar profile
. He serves continuously as reviewer for internationally reputed journals. In addition to the funding of the LBG and partner institutions towards the LBI-CR, he has been responsible to obtain more than 2.5 M€ of external funding towards his research.
RM is director and founding member of the LBI-CR. He runs his own research group since 2006, which is focused on the JAK-STAT core cancer pathway. The group studies hematopoietic cancer, melanoma, sarcoma, colon and liver cancer. Molecular mechanisms of transcription factors and kinases are studied to gain insights into mechanisms of action to control metabolism, cellular proliferation/survival, PI3K-Akt activation in context of cancer establishment and progression.
Dr. Moriggl studied biotechnology in Germany and did his PhD in 1997 working on cytokine signaling with Prof. Groner, Friedrich Miescher Institute, Basel, Switzerland and Institute of Experimental Cancer Research, Freiburg, Germany. After a postdoctoral fellowship at St. Jude Children’s Research Hospital in Memphis, USA, in the area of immunology with Prof. Ihle he moved 2000 to the group of Prof. Beug, Institute for Molecular Pathology, in Vienna. There he studied hematopoiesis and hematopoietic cancer development through oligomeric STAT5. Moreover, he made important contributions to the essential interaction of the hepatic glucocorticoid receptor with STAT5 for body growth, sexual differentiation and metabolism. He heads the Ludwig Boltzmann Institute for Cancer Research (LBI-CR) since 2005. RM obtained the Howard Hughes Medical Institute Postdoctoral Fellowship from 1997 to 2000 and a Marie Curie Industrial Host Fellowship from 2000 to 2002.
RM is recipient of several prestigious awards including the "Max Buchner-Forschungspreis” (1992), “Otto-Kraupp-Preis” for the Venia Docendi of the Medical Faculty, University of Vienna (2004), “Award of the city of Vienna for research achievements” (2008) and for outstanding scientific achievements in cancer research “Großer zentraleuropäischer Preis”, Fonds der Stadt Wien für innovative interdisziplinäre Krebsforschung (2013).
The CV of Richard Moriggl is available here.
RM participates in two special research programmes (SFB) of the Austrian Science Fund:
SFB-F28: Jak-Stat Signalling
SFB F28 ran from 2006 to 2016 and is now successfully completed. It was headed by Prof. Mathias Müller from the Vetmeduni Vienna with deputy speaker Prof. Thomas Decker from the Max Perutz Laboratories. The final report is publicly available on the project website.
The particular strength of the research was to apply the fundamental knowledge about Jak-Stat mechanisms in cellular processes to the next level of complexity. The strength of SFB-JakStat was and the contributing research teams remains the pathway-centric view on molecular mechanistics, disease causalities and therapeutic interventions. The national and international renowned collaborative network that developed over the past decade will be further fostered by the long-term members of the consortium. The regular meetings with external speakers and progress reports of the JAK-STAT centric groups will be perpetuated. Most importantly, the core members of the consortium have sumitted a follow-up SFB concept termed Monarchie and Hierarchies in Shaping Chromatin Landscapes, which was invited to submit a full length proposal.
please click on the image for an animated introduction to the Jak/STAT pathway
SFB-F47: Myeloproliferative Neoplasias
The general aim of the SFB F47 is to identify and characterize novel clinically relevant markers and targets in patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) and other myeloproliferative neoplasms (MPN), thereby providing novel tools and strategies for the development of improved diagnostic and therapeutic approaches.
The well-established biology of Ph+ CML will be employed as a paradigmatic model to study the evolution of leukemic stem cells (LSC) and the mechanisms underlying progression and drug-resistance in the SFB research program. The ultimate aim of the SFB is to improve targeted therapies in CML and other MPN by developing novel LSC-eradicating treatment concepts.
The researchers of the SFB-F47 at its kick-off meeting in 2013.